ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

Phase 2

Terminated

• Conditions: HPV-Induced Genital Lesions
• Interventions: Drug: Vehicle; Drug: CLS003

• Registration Number: NCT03334240
• Lead Sponsor: Maruho Co., Ltd.

Brief Summary

This study is intended to explore and evaluate the pharmacodynamics and clinical efficacy of the ionic contra-viral therapy CLS003 in immunocompromised and immunocompetent patients with benign and premalignant HPV-induced genital lesions

Detailed Description

This study is intended to explore clinical efficacy and safety/tolerability of ICVT as a potential treatment for benign and premalignant HPV-induced genital lesions in immunocompetent and immunosuppressed patients. This includes 3 different patient populations: i) immunocompetent patients with anogenital warts (AGWs), ii) immunocompromised patients with anogenital warts and iii) immunocompromised patients with vulvar high grade squamous intraepithelial neoplasia (HSIL), formerly referred to as usual type vulvar intraepithelial neoplasia (uVIN). Since digoxin / furosemide ICVT's mode of action is in part independent of the immune system and directly targeted to eradicate the causative HPV, we hypothesize this therapy to be of value in this specific group of individuals.

Study Timeline

• Study Start: 2017-10-05
• Study First Submitted: 2017-10-30
• Study First Submitted QC: 2017-11-06
• Study First Posted: 2017-11-07
• Primary Completion: 2018-10-30
• Study Completion: 2018-10-30
• Status Verified: 2019-03
• Last Update Submitted: 2019-03-18
• Last Update Posted: 2019-03-20

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

1. Patients ≥ 18 years in general, stable good health (with the exception of the immunocompromised disorder) as per judgment of the investigator based upon the results of a medical history, physical examination, ECG, chemistry, hematology.
2. In case of immunocompromised patients including but not limited to; patients receiving immunosuppressive therapy for any reason, patients with auto-immune disease, HIV patients, transplantation patients
3. In case of genital warts patient group(s): have at least 3 genital warts (only applicable to Study Part 1)
4. In case of vulvar HSIL: at least one lesion that can be accurately measured in at least one dimension with longest diameter ≥ 20 mm OR in 2 perpendicular dimensions that when multiplied together give a surface area ≥ 120 mm² (only applicable to Study Part 1)
5. If female of childbearing potential, have a negative urine pregnancy test at Screening and Day 0, and is willing to use effective contraception during the study and 3 months afterwards (i.e. oral, implanted, injectable, IUD, diaphragm, condom, tubal ligation, abstinence, or are in a monogamous relationship with a partner who has had a vasectomy)
6. Able to participate and willing to give written informed consent and to comply with the study restrictions
7. Ability to communicate well with the investigator in the Dutch language
8. Willing to refrain from using other topical products in the treatment area, or prohibited medications for the duration of the study

Read More

Exclusion Criteria

1. Significant, uncontrolled or unstable disease in any organ system as per judgment of the investigator (regardless of association with the immunosuppressing disorder/therapy), including but not limited to: psychiatric, neurologic, cardiovascular, pulmonary, gastrointestinal, hepatic, renal, endocrine, hematologic or respiratory disease
2. Have used or received any topical genital wart treatment, cryotherapy, electrocoagulation, surgery in the treatment area within 28 days prior to enrolment
3. Have used or received any topical vulvar HSIL treatment, laser therapy or surgery in the treatment area within 28 days prior to enrolment
4. Have any current relevant skin infections in the treatment area other than genital warts (inclusively, but not limited to atopic dermatitis, lichen sclerosis, lichen planus or psoriasis)
5. Have a known sensitivity to any of the investigational product ingredients, including digoxin and furosemide
6. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times in the past year
7. Loss or donation of blood over 500 mL within three months prior to screening.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Vehicle	Vehicle	Inactive vehicle
CLS003	CLS003	Digoxin and Furosemide topical formulation

Primary Outcome Measures

Name	Time	Method
Change in patient-reported outcomes	Through study completion, up to 20 weeks
HPV viral load assessment	Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)
Mean HPV viral load	Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)
Histology (regression of vulvar HSIL or AGWs to no dysplasia, HPV genotyping)	Day 0, 42, 126, (Part 1 of study), Day 56 (Part 2 of study)
Percentage clearance of vulvar HSIL lesions	Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)	For vulvar HSIL cohort
Proportion of patients with all vulvar HSIL lesions cleared	Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)	For vulvar HSIL cohort
Clinical recurrence in the Part 1 follow-up period	Day 84, 126	For genital wart cohort
Lesion (vulvar HSIL or wart) size reduction	Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)
Change in the HPV viral load	Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)
Local immunity status	Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)
Histology (regression of vulvar HSIL to no dysplasia)	Day 0, 42, 126, (Part 1 of study), Day 56 (Part 2 of study)	For vulvar HSIL cohort
Histological recurrence in the Part 1 follow-up period	Day 84, 126	For vulvar HSIL cohort
Percentage clearance of genital warts	Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)	For genital wart cohort
Proportion of patients with all genital warts cleared	Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study)	For genital wart cohort

Secondary Outcome Measures

Name	Time	Method
Adverse event collection to assess safety/tolerability of CLS003	Day 0, 21, 42, 84, 126, (Part 1 of study), Day 0, 28, 56, 140 (Part 2 of study), and as volunteered by patient

Trial Locations

Locations (1)

LUMC/Centre For Human Drug Research; 🇳🇱 Leiden, Netherlands